Eleven-Nineteen-Leukemia Protein IN-2

Cat. No.: HY-152470: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Eleven-Nineteen-Leukemia Protein IN-2 (compound 23) is an Eleven-Nineteen-Leukemia Protein (ENL) inhibitor with an IC₅₀ value of 10.7 nM. Eleven-Nineteen-Leukemia Protein IN-2 can be used for the research of leukemia.

For research use only. We do not sell to patients.

Eleven-Nineteen-Leukemia Protein IN-2 Chemical Structure

CAS No. : 2894121-78-7

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	Eleven-Nineteen-Leukemia Protein IN-2 (compound 23) is an Eleven-Nineteen-Leukemia Protein (ENL) inhibitor with an IC₅₀ value of 10.7 nM. Eleven-Nineteen-Leukemia Protein IN-2 can be used for the research of leukemia^[1].
In Vitro	Eleven-Nineteen-Leukemia Protein IN-2 (0-1000 nM) shows ENL inhibitory activity with an IC₅₀ value of 10.7 nM^[1]. Eleven-Nineteen-Leukemia Protein IN-2 (0-1000 μM; 72 hours) inhibits activity of MOLM-13 cells with an IC₅₀ value of 37.9 μM^[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Eleven-Nineteen-Leukemia Protein IN-2 Related Antibodies
Molecular Weight	389.45
Formula	C₂₂H₂₃N₅O₂
CAS No.	2894121-78-7
SMILES	CC1=NOC2=CC(C(NC3=CC=C4NC(CN5CCC[C@@H]5C)=NC4=C3)=O)=CC=C21
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (266 KB) Handling Instructions (2659 KB)
References	[1]. Guo S, et al. Design, synthesis of novel benzimidazole derivatives as ENL inhibitors suppressing leukemia cells viability via downregulating the expression of MYC. Eur J Med Chem. 2023 Feb 15;248:115093. [Content Brief]